The Zhitong Finance App learned that Weilizhibo-B (09887) rose more than 9%. As of press release, it had risen 13.28% to HK$67.4, with a turnover of HK$93.961 million.
According to the news, Weilizhibo announced that six of its latest research results were selected for the 2026 European Society of Medical Oncology (ESMO) Annual Meeting. Of the six studies selected this time, two were selected for the highest-standard oral presentation and four for poster presentations, covering treatment areas such as extrapulmonary neuroendocrine cancer (EP-NEC), biliary tract cancer (BTC), and recurrent/refractory multiple myeloma (RRMM). Additionally, the company has been awarded the Latest Breakthrough Summary (LBA) status and will submit the full LBA in September 2026. The company previously announced that LBL-024 was selected by 1L NSCLC to hold an oral report at the World Lung Cancer Conference (WCLC) in September this year
On July 10, Weilizhibo announced that the PD-L1/4-1BB bispecific antibody Villixine® (LBL-024) biologic product marketing license application (BLA) for treating advanced extrapulmonary neuroendocrine cancer (EP-NEC) independently developed by the company was approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for inclusion in the priority review and approval process. According to the company, this milestone marks the official closure of the commercialization schedule for Velisign®, and the approval period for listing can clearly be expected. At the same time, Weilizhibo is actively promoting various commercialization preparations before listing.